Literature DB >> 24839323

Monitoring progress towards the elimination of measles in China: an analysis of measles surveillance data.

Chao Ma1, Lixin Hao1, Yan Zhang2, Qiru Su1, Lance Rodewald3, Zhijie An1, Wenzhou Yu1, Jing Ma1, Ning Wen1, Huiling Wang2, Xiaofeng Liang2, Huaqing Wang1, Weizhong Yang2, Li Li1, Huiming Luo1.   

Abstract

OBJECTIVE: To analyse the epidemiology of measles in China and determine the progress made towards the national elimination of the disease.
METHODS: We analysed measles surveillance data - on the age, sex, residence and vaccination status of each case and the corresponding outcome, dates of onset and report and laboratory results - collected between January 2005 and October 2013.
FINDINGS: Between 2005 and October 2013, 596 391 measles cases and 368 measles-related deaths were reported in China. Annual incidence, in cases per 100 000 population, decreased from 9.95 in 2008 to 0.46 in 2012 but then rose to more than 1.96 in 2013. The number of provinces that reported an annual incidence of less than one case per million population increased from one in 2009 to 15 in 2012 but fell back to one in 2013. Median case age decreased from 83 months in 2005 to 14 months in 2012 and 11 months in January to October 2013. Between 2008 and 2012, the incidence of measles in all age groups, including those not targeted for vaccination, decreased by at least 93.6%. However, resurgence started in late 2012 and continued into 2013. Of the cases reported in January to October 2013, 40% were aged 8 months to 6 years.
CONCLUSION: Although there is evidence of progress towards the elimination of measles from China, resurgence in 2013 indicated that many children were still not being vaccinated on time. Routine immunization must be strengthened and the remaining immunity gaps need to be identified and filled.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24839323      PMCID: PMC4007128          DOI: 10.2471/BLT.13.130195

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  19 in total

1.  Assessment of the 2010 global measles mortality reduction goal: results from a model of surveillance data.

Authors:  Emily Simons; Matthew Ferrari; John Fricks; Kathleen Wannemuehler; Abhijeet Anand; Anthony Burton; Peter Strebel
Journal:  Lancet       Date:  2012-04-24       Impact factor: 79.321

2.  Monitoring progress towards measles elimination.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2010-12-03

Review 3.  The role of measles elimination in development of a national immunization program.

Authors:  Walter A Orenstein
Journal:  Pediatr Infect Dis J       Date:  2006-12       Impact factor: 2.129

4.  Measles in Europe: an epidemiological assessment.

Authors:  Mark Muscat; Henrik Bang; Jan Wohlfahrt; Steffen Glismann; Kåre Mølbak
Journal:  Lancet       Date:  2009-01-07       Impact factor: 79.321

5.  Progress towards the 2012 measles elimination goal in WHO's Western Pacific Region, 1990-2008.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2009-07-03

6.  Global reductions in measles mortality 2000-2008 and the risk of measles resurgence.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2009-12-04

7.  Progress toward measles elimination in the People's Republic of China, 2000-2009.

Authors:  Chao Ma; Zhijie An; Lixin Hao; K Lisa Cairns; Yan Zhang; Jing Ma; Lei Cao; Ning Wen; Wenbo Xu; Xiaofeng Liang; Weizhong Yang; Huiming Luo
Journal:  J Infect Dis       Date:  2011-07       Impact factor: 5.226

8.  Large outbreak of measles in a community with high vaccination coverage: implications for the vaccination schedule.

Authors:  Angela Domínguez; Nuria Torner; Irene Barrabeig; Ariadna Rovira; Cristina Rius; Joan Cayla; Elsa Plasencia; Sofia Minguell; M Rosa Sala; Ana Martínez; Josep Costa; Mar Mosquera; Carmen Cabezas
Journal:  Clin Infect Dis       Date:  2008-11-01       Impact factor: 9.079

9.  Immunization status and risk factors of migrant children in densely populated areas of Beijing, China.

Authors:  Meiping Sun; Rui Ma; Yang Zeng; Fengji Luo; Jing Zhang; Wenjun Hou
Journal:  Vaccine       Date:  2009-11-24       Impact factor: 3.641

10.  Single endemic genotype of measles virus continuously circulating in China for at least 16 years.

Authors:  Yan Zhang; Songtao Xu; Huiling Wang; Zhen Zhu; Yixin Ji; Chunyu Liu; Xiaojie Zhang; Liwei Sun; Jianhui Zhou; Peishan Lu; Ying Hu; Daxing Feng; Zhenying Zhang; Changyin Wang; Xueqiang Fang; Huanying Zheng; Leng Liu; Xiaodong Sun; Wei Tang; Yan Wang; Yan Liu; Hui Gao; Hong Tian; Jiangtao Ma; Suyi Gu; Shuang Wang; Yan Feng; Fang Bo; Jianfeng Liu; Yuan Si; Shujie Zhou; Yuyan Ma; Shengwei Wu; Shunde Zhou; Fangcai Li; Zhengrong Ding; Zhaohui Yang; Paul A Rota; David Featherstone; Youngmee Jee; William J Bellini; Wenbo Xu
Journal:  PLoS One       Date:  2012-04-20       Impact factor: 3.240

View more
  50 in total

1.  Pre-vaccination evolution of antibodies among infants 0, 3 and 6months of age: A longitudinal analysis of measles, enterovirus 71 and coxsackievirus 16.

Authors:  Chuanxi Fu; Jichuan Shen; Long Lu; Yajing Li; Yimin Cao; Ming Wang; Sen Pei; Zhicong Yang; Qing Guo; Jeffrey Shaman
Journal:  Vaccine       Date:  2017-06-10       Impact factor: 3.641

2.  Comparative assessment of immunization coverage of migrant children between national immunization program vaccines and non-national immunization program vaccines in East China.

Authors:  Yu Hu; Shuying Luo; Xuewen Tang; Linqiao Lou; Yaping Chen; Jing Guo
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Evaluating vaccination policies to accelerate measles elimination in China: a meta-population modelling study.

Authors:  Lixin Hao; John W Glasser; Qiru Su; Chao Ma; Zhilan Feng; Zundong Yin; James L Goodson; Ning Wen; Chunxiang Fan; Hong Yang; Lance E Rodewald; Zijian Feng; Huaqing Wang
Journal:  Int J Epidemiol       Date:  2019-08-01       Impact factor: 7.196

4.  Outbreak of measles among persons with secondary vaccine failure, China, 2018.

Authors:  Zhujiazi Zhang; Meng Chen; Rui Ma; Jingbin Pan; Luodan Suo; Li Lu
Journal:  Hum Vaccin Immunother       Date:  2019-09-05       Impact factor: 3.452

5.  Risk factors for measles among infants in Tianjin, China.

Authors:  Y Zhang; A L Wagner; X Wang; B F Carlson; Y Ding; J P Montgomery; B W Gillespie; M L Boulton
Journal:  Public Health       Date:  2017-08-04       Impact factor: 2.427

6.  A population profile of measles susceptibility in Tianjin, China.

Authors:  Matthew L Boulton; Xiexiu Wang; Ying Zhang; JoLynn P Montgomery; Abram L Wagner; Bradley F Carlson; Yaxing Ding; Xiaoyan Li; Brenda Gillespie; Xu Su
Journal:  Vaccine       Date:  2016-05-03       Impact factor: 3.641

7.  Risk factors for measles in children aged 8 months-14 years in China after nationwide measles campaign: A multi-site case-control study, 2012-2013.

Authors:  Lixin Hao; Chao Ma; Kathleen A Wannemuehler; Qiru Su; Zhijie An; Lisa Cairns; Linda Quick; Lance Rodewald; Yuanbao Liu; Hanqing He; Qing Xu; Yating Ma; Wen Yu; Ningjing Zhang; Li Li; Ning Wang; Huiming Luo; Huaqing Wang; Christopher J Gregory
Journal:  Vaccine       Date:  2016-02-11       Impact factor: 3.641

8.  Measles vaccination of young infants in China: A cost-effectiveness analysis.

Authors:  Cara Bess Janusz; Abram L Wagner; Nina B Masters; Yaxing Ding; Ying Zhang; David W Hutton; Matthew L Boulton
Journal:  Vaccine       Date:  2020-05-22       Impact factor: 3.641

9.  The impact of supplementary immunization activities on the epidemiology of measles in Tianjin, China.

Authors:  Abram L Wagner; Ying Zhang; Bhramar Mukherjee; Yaxing Ding; Eden V Wells; Matthew L Boulton
Journal:  Int J Infect Dis       Date:  2016-03-10       Impact factor: 3.623

10.  A Population-Based Acute Meningitis and Encephalitis Syndromes Surveillance in Guangxi, China, May 2007-June 2012.

Authors:  Yihong Xie; Yi Tan; Virasakdi Chongsuvivatwong; Xinghua Wu; Fuyin Bi; Stephen C Hadler; Chuleeporn Jiraphongsa; Vorasith Sornsrivichai; Mei Lin; Yi Quan
Journal:  PLoS One       Date:  2015-12-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.